Advances in antibody drugs for treatment of melanoma

XU Jingwen; JIANG Huici; CHEN Ximin; DING Guipeng

doi:10.11665/j.issn.1000-5048.20140302

XU Jingwen, JIANG Huici, CHEN Ximin, DING Guipeng. Advances in antibody drugs for treatment of melanoma[J]. Journal of China Pharmaceutical University, 2014, 45(3): 259-266. DOI: 10.11665/j.issn.1000-5048.20140302

Citation:

XU Jingwen, JIANG Huici, CHEN Ximin, DING Guipeng. Advances in antibody drugs for treatment of melanoma[J]. Journal of China Pharmaceutical University, 2014, 45(3): 259-266. DOI: 10.11665/j.issn.1000-5048.20140302

Citation:

XU Jingwen, JIANG Huici, CHEN Ximin, DING Guipeng. Advances in antibody drugs for treatment of melanoma[J]. Journal of China Pharmaceutical University, 2014, 45(3): 259-266. DOI: 10.11665/j.issn.1000-5048.20140302

Advances in antibody drugs for treatment of melanoma

Graphical Abstract

Graphical Abstract

Abstract

Abstract

Antibody drugs play an important role in the treatment of melanoma. Some antibodies such as anti CTLA-4 antibodies(ipilimumab and tremelimumab)and anti PD-1 antibodies(nivolumab and lambrolizumab)have been evaluated under phase III clinical trials. This review briefly discusses recent development and advances of antibody drugs against melanoma.

FullText(HTML)

References (21)

Advances in antibody drugs for treatment of melanoma

Graphical Abstract

Abstract

Catalog

Export File

Citation

Format

Content